Stockreport

ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia

ContraFect Corporation  (CFRX) 
Last contrafect corporation earnings: 3/18 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.contrafect.com
PDF YONKERS, NY -- (Marketwired) -- 05/25/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and [Read more]